X4 Pharmaceuticals (NASDAQ:XFOR) Upgraded by Wells Fargo & Company to Strong-Buy Rating

Wells Fargo & Company upgraded shares of X4 Pharmaceuticals (NASDAQ:XFOR) to a strong-buy rating in a research report sent to investors on Friday morning,Zacks.com reports.

A number of other research analysts have also commented on XFOR. Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 23rd. Leerink Partners initiated coverage on X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 target price for the company. Finally, Wall Street Zen raised X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.70.

X4 Pharmaceuticals Price Performance

Shares of XFOR stock opened at $4.41 on Friday. X4 Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $4.83. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45. The firm’s 50 day moving average is $4.07 and its 200-day moving average is $3.95. The firm has a market capitalization of $415.95 million, a price-to-earnings ratio of -0.97 and a beta of 0.35.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The business had revenue of $2.71 million during the quarter, compared to analyst estimates of $3.20 million. Sell-side analysts forecast that X4 Pharmaceuticals will post -0.77 EPS for the current fiscal year.

Insider Activity

In related news, CFO David Kirske sold 8,543 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total value of $36,393.18. Following the completion of the sale, the chief financial officer owned 167,750 shares in the company, valued at $714,615. This represents a 4.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.13% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XFOR. Empery Asset Management LP acquired a new stake in shares of X4 Pharmaceuticals during the fourth quarter worth about $35,804,000. Bain Capital Life Sciences Investors LLC grew its position in shares of X4 Pharmaceuticals by 227.0% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company’s stock valued at $31,870,000 after purchasing an additional 5,530,866 shares during the period. Perceptive Advisors LLC grew its position in shares of X4 Pharmaceuticals by 6.7% in the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock valued at $27,826,000 after purchasing an additional 423,196 shares during the period. Kalehua Capital Management LLC acquired a new position in shares of X4 Pharmaceuticals in the 4th quarter valued at approximately $14,891,000. Finally, Braidwell LP bought a new stake in X4 Pharmaceuticals during the 4th quarter worth approximately $13,476,000. 72.03% of the stock is owned by institutional investors and hedge funds.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.